Pfizer halts biosimilar programs in crowded China market, sells plant to WuXi Biologics

China only approved its first biosimilar drug in 2019, but the market is already looking too crowded for one Big Pharma company.

Pfizer has halted its biosimilar programs in China and is selling a biologics facility there to Chinese CDMO giant WuXi Biologics, the company said in a statement Wednesday.